 |
|
|
| |
Non inferiority of dolutegravir+emtricitabine dual therapy
to standard combination antiretroviral therapy
in maintaining HIV suppression throughout 48 weeks:
The SIMPL'HIV study
|
| |
| |
17th European AIDS Conference, November 6-9, 2019, Basel
Reported by Jules Levin
|
| |
|
|
|
|
|
